These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations). Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697 [TBL] [Abstract][Full Text] [Related]
8. Rationale and design of the PRAETORIAN trial: a Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. Olde Nordkamp LR; Knops RE; Bardy GH; Blaauw Y; Boersma LV; Bos JS; Delnoy PP; van Dessel PF; Driessen AH; de Groot JR; Herrman JP; Jordaens LJ; Kooiman KM; Maass AH; Meine M; Mizusawa Y; Molhoek SG; van Opstal J; Tijssen JG; Wilde AA Am Heart J; 2012 May; 163(5):753-760.e2. PubMed ID: 22607851 [TBL] [Abstract][Full Text] [Related]
9. [Initial clinical results with a novel implantable cardioverter-defibrillator: a prospective evaluation in 3 Swiss university hospitals]. Osswald S; Candinas R; Fuhrer J Schweiz Med Wochenschr; 1995 Dec; 125(50):2423-32. PubMed ID: 8553030 [TBL] [Abstract][Full Text] [Related]
10. Incidence and causes of inappropriate detection and therapy by implantable defibrillators of cardioversion in patients with ventricular tachyarrhythmia. Chen RH; Chen KP; Wang FZ; Hua W; Chen X; Zhang S Chin Med J (Engl); 2006 Apr; 119(7):557-63. PubMed ID: 16620696 [TBL] [Abstract][Full Text] [Related]
11. [Complications in transvenous and transvenous-subcutaneous implantable defibrillator systems]. Podczeck A; Hief C; Veit F; Jakl G; Kaltenbrunner W; Nürnberg M; Frohner K; Steinbach K Z Kardiol; 1994 May; 83(5):366-72. PubMed ID: 8053246 [TBL] [Abstract][Full Text] [Related]
12. Effect of an active abdominal pulse generator on defibrillation thresholds with a dual-coil, transvenous ICD lead system. Rashba EJ; Farasat M; Kirk MM; Shorofsky SR; Peters RW; Gold MR J Cardiovasc Electrophysiol; 2006 Jun; 17(6):617-20. PubMed ID: 16836709 [TBL] [Abstract][Full Text] [Related]
13. Development of the subcutaneous implantable cardioverter-defibrillator for reducing sudden cardiac death. Sanghera R; Sanders R; Husby M; Bentsen JG Ann N Y Acad Sci; 2014 Nov; 1329():1-17. PubMed ID: 25308791 [TBL] [Abstract][Full Text] [Related]
14. [Implantable cardioverter-defibrillators in patients resuscitated from sudden death and in patients with sustained refractory ventricular tachycardia]. Adragão P; Parreira L; Neves J; Morgado F; Abecassis M; Almeida M; Martins D; Bonhorst D; Seabra-Gomes R Rev Port Cardiol; 1996 Mar; 15(3):195-206, 179, 181. PubMed ID: 8634168 [TBL] [Abstract][Full Text] [Related]
15. The innominate vein as alternative venous access for complicated implantable cardioverter defibrillator revisions. Aleksic I; Kottenberg-Assenmacher E; Kienbaum P; Szabo AK; Sommer SP; Wieneke H; Yildirim C; Leyh RG Pacing Clin Electrophysiol; 2007 Aug; 30(8):957-60. PubMed ID: 17669077 [TBL] [Abstract][Full Text] [Related]
16. High defibrillation threshold in patients with implantable defibrillator: how effective is the subcutaneous finger lead? Osswald BR; De Simone R; Most S; Tochtermann U; Tanzeem A; Karck M Eur J Cardiothorac Surg; 2009 Mar; 35(3):489-92. PubMed ID: 19144533 [TBL] [Abstract][Full Text] [Related]
17. [Cardioverter-defibrillator implantations without thoracotomy: clinical experience with various electrode configurations and defibrillation wave forms of an endocardial/subcutaneous defibrillator system]. Neuzner J; Huth C; Friedl A; Reinisch P; Pitschner HF; Schlepper M Z Kardiol; 1993 Feb; 82(2):99-107. PubMed ID: 8465572 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Weiss R; Knight BP; Gold MR; Leon AR; Herre JM; Hood M; Rashtian M; Kremers M; Crozier I; Lee KL; Smith W; Burke MC Circulation; 2013 Aug; 128(9):944-53. PubMed ID: 23979626 [TBL] [Abstract][Full Text] [Related]
19. Long-term experience with subcutaneous ICD leads: a comparison among three different types of subcutaneous leads. Kettering K; Mewis C; Dörnberger V; Vonthein R; Bosch RF; Seipel L; Kühlkamp V Pacing Clin Electrophysiol; 2004 Oct; 27(10):1355-61. PubMed ID: 15511244 [TBL] [Abstract][Full Text] [Related]
20. Upper limit of vulnerability is a good estimator of shock strength associated with 90% probability of successful defibrillation in humans with transvenous implantable cardioverter-defibrillators. Swerdlow CD; Ahern T; Kass RM; Davie S; Mandel WJ; Chen PS J Am Coll Cardiol; 1996 Apr; 27(5):1112-8. PubMed ID: 8609329 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]